Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14788010 | 0.93 | BACE1 (0.71) | BACE1 | |
| SCHEMBL14787986 | 0.92 | BACE1 (0.71) | BACE1 | |
| SCHEMBL14788022 | 0.92 | BACE1 (0.69) | BACE1 | |
| SCHEMBL14788039 | 0.91 | BACE1 (0.76) | BACE1 | |
| SCHEMBL18707878 | 0.90 | BACE1 (1.00) | BACE1 | |
| SCHEMBL16043733 | 0.90 | BACE1 (1.00) | BACE1 | |
| SCHEMBL18707549 | 0.90 | BACE1 (1.00) | BACE1 | |
| SCHEMBL18707869 | 0.90 | BACE1 (1.00) | BACE1 | |
| SCHEMBL16041457 | 0.90 | BACE1 (1.00) | BACE1 | |
| SCHEMBL14787973 | 0.90 | BACE1 (0.83) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476264-B2 | N-(3-(2-amino-6,6-difluoro-4,4A,5,6,7,7A-hexahydro-cyclopenta[E][1,3]oxazin-4-yl)-phenylamides as BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476264-B2 | N-(3-(2-amino-6,6-difluoro-4,4A,5,6,7,7A-hexahydro-cyclopenta[E][1,3]oxazin-4-yl)-phenylamides as BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130072478-A1 | N-(3-(2-AMINO-6,6-DIFLUORO-4,4A,5,6,7,7A-HEXAHYDRO-CYCLOPENTA[E][1,3]OXAZIN-4-YL)-PHENYL-AMIDES AS BACE1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-21 | — | — | US | disclosed |
| US-20130072478-A1 | N-(3-(2-AMINO-6,6-DIFLUORO-4,4A,5,6,7,7A-HEXAHYDRO-CYCLOPENTA[E][1,3]OXAZIN-4-YL)-PHENYL-AMIDES AS BACE1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072478-A1 | N-(3-(2-AMINO-6,6-DIFLUORO-4,4A,5,6,7,7A-HEXAHYDRO-CYCLOPENTA[E][1,3]OXAZIN-4-YL)-PHENYL-AMIDES AS BACE1 INHIBITORS | BACE1, BACE2, PSEN1 | BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.